CSL Recently announced plans to demerge its Seqirus vaccine division and cut 3,000 jobs. Despite rising profits, this led to a sharp ~17% drop in its share price on August 19, 2025.Its volatility and large capital moves make it a prime candidate for swing trading—especially if it breaks key technical levels like above A$315 (a potential trigger to the A$400 range)
